Phase III clinical trial - Gynécologie

AGO-OVAR 2.29
Gynécologie
Ouvert depuis le: 11.27.2021
Site: Paris
Public cible
Adulte
Atezolizumab in combination with Bevacizumab and Chemotherapy;versus Bevacizumab and Chemotherapy;in recurrent ovarian cancer À a randomized Phase III trial;An ENGOT Trial
Description de l'essai

The AURELIA trial showed a significant PFS benefit of adding bevacizumab to monochemotherapy in this patient cohort (HR 0.48; 95%CI 0.38-0.60; p<0.001) (4). Therefore, bevacizumab based treatment is a new standard option in patients;with platinum-resistant ovarian cancer.